GSK drops GSK2586184 for autoimmune indications
Galapagos N.V. (Euronext:GLPG; Pink:GLPYY) disclosed in its 2Q14 earnings that partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) discontinued development of oral GSK2586184 for all current indications -- systemic lupus erythematosus (SLE), ulcerative colitis (UC) and psoriasis. According to Galapagos, GSK decided to discontinue the UC and psoriasis indications as a result of a statin drug-drug interaction study. In February, GSK placed a Phase I/II trial for UC on hold and discontinued a Phase II trial of GSK2586184 to treat SLE due to "lack of effect."
GSK said it is exploring development options for the Janus kinase-1 (JAK-1) inhibitor in other indications. In April, GSK2586184 met the primary endpoint in the Phase IIa JAK116679 trial to treat chronic plaque psoriasis (see BioCentury Extra, April 17). ...